NCT06531798View on ClinicalTrials.gov

Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

October 30, 2026

Study Completion Date

December 30, 2027

Conditions
Moderate to Severe COPD
Interventions
DRUG

Breztri Aerosphere

Budesonide 160 mcg/Glycopyrrolate 7.2 mcg/Formoterol fumarate dehydrate 5 mcg

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY